Orexo appoints Carl-Johan Blomberg as new Chief Financial Officer

Uppsala, Sweden, August 31, 2011 – Orexo AB (STO: ORX) appoints Carl-Johan Blomberg as new Chief Financial Officer, effective September 1. Carl-Johan Blomberg will take overall responsibility for the Group's Finance and Administration function, including IR and IT and will be part of the executive management team.

Carl-Johan has many years extensive experience in Finance from various industries, such as engineering, electronics and pharmaceuticals. Most recently he held the position of CFO at Micronic Mydata, and has earlier held Financial Director positions within Alfa‑Laval, Procordia and Pharmacia & Upjohn.

“We are very pleased with the recruitment of Carl-Johan as our new CFO. He brings broad experience and will play a key role in the future development of Orexo,” says Anders Lundström, President and CEO of Orexo AB.

Contact details:
Anders Lundström, President and CEO, Orexo AB
Tel: +46 706 67 22 66
Email: anders.lundstrom@orexo.com

About Orexo
Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four commercialized products, several projects developed in partnership as well as three proprietary development programs. Orexo’s registered products are Abstral® for the treatment of break through cancer pain, sold by Kyowa Hakko Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill Edluar™, sold by Meda in the USA, as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary Kibion. More information can be found at www.orexo.com.

Orexo AB (publ) discloses the information provided in this press release pursuant to the Securities Markets Act. The information was provided for public release on August 31, 2011 at 11:15a.m. CET. This press release has been prepared in both Swedish and English. In the event of any discrepancy in the content of the two versions, the Swedish version shall take precedence